The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesWB: Use at a concentration of 1-5 µg/ml. IHC-P: Use at a concentration of 3 µg/ml.
Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
RelevanceRNF139 is a multi-membrane spanning protein E3 ubiquitin ligase which is mutated in clear-cell renal carcinomas. It contains a sterol-sensing domain and a RING-H2 motif essential for ubiquitin ligase activity. It is a potential tumor suppressor for renal cell carcinoma. Human kidney cells are growth inhibited by RNF139. Inhibition is manifested by G2/M arrest and is dependent upon the ubiquitin ligase activity of the RING domain. Expression of RNF139 represses genes involved in cholesterol and fatty acid biosynthesis that are transcriptionally regulated by the sterol response element binding proteins (SREBPs). RNF139 modulation of SREBP activity comprises a novel regulatory link between growth control and the cholesterol/lipid homeostasis pathway.
RNF139 antibody (ab56924) used in immunohistochemistry at 3ug/ml on formalin fixed and paraffin embedded human tonsil.
Western blot - RNF139 antibody (ab56924)
Predicted band size : 76 kDa RNF139 antibody (ab56924) at 1ug/lane + HepG2 cell lysate at 25ug/lane.
References for Anti-RNF139 antibody (ab56924)
This product has been referenced in:
Gimelli S et al. The tumor suppressor gene TRC8/RNF139 is disrupted by a constitutional balanced translocation t(8;22)(q24.13;q11.21) in a young girl with dysgerminoma. Mol Cancer8:52 (2009).
Read more (PubMed: 19642973) »